Analyzing Edap Tms (EDAP) and Sunshine Heart (CHFS)

Edap Tms (NASDAQ: EDAP) and Sunshine Heart (NASDAQ:CHFS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.

Analyst Ratings

How to Become a New Pot Stock Millionaire

This is a breakdown of recent ratings and price targets for Edap Tms and Sunshine Heart, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edap Tms 0 0 1 0 3.00
Sunshine Heart 0 0 1 0 3.00

Edap Tms currently has a consensus target price of $7.00, indicating a potential upside of 208.97%. Sunshine Heart has a consensus target price of $65.00, indicating a potential upside of 2,066.67%. Given Sunshine Heart’s higher probable upside, analysts plainly believe Sunshine Heart is more favorable than Edap Tms.

Volatility & Risk

Edap Tms has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Sunshine Heart has a beta of 2.25, meaning that its share price is 125% more volatile than the S&P 500.

Insider and Institutional Ownership

9.4% of Edap Tms shares are held by institutional investors. Comparatively, 9.2% of Sunshine Heart shares are held by institutional investors. 2.0% of Sunshine Heart shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Edap Tms and Sunshine Heart’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Edap Tms $40.74 million 1.61 -$770,000.00 ($0.01) -226.56
Sunshine Heart $3.55 million 3.21 -$13.38 million ($37.15) -0.08

Edap Tms has higher revenue and earnings than Sunshine Heart. Edap Tms is trading at a lower price-to-earnings ratio than Sunshine Heart, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Edap Tms and Sunshine Heart’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Edap Tms -2.12% 23.25% 12.92%
Sunshine Heart -376.64% -146.41% -112.90%

Summary

Edap Tms beats Sunshine Heart on 7 of the 11 factors compared between the two stocks.

About Edap Tms

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS). The HIFU division develops, manufactures, and markets devices for the minimally invasive destruction of various types of localized tumors using HIFU technology. It offers Ablatherm, a HIFU device for the treatment of organ-confined prostate cancer, referred to as T1-T2 stage; and Focal One device, a HIFU robotic device for the focal therapy of localized prostate cancer. This division also leases equipment; sells disposables and spare parts; and offers maintenance services. The UDS division develops, manufactures, markets, and services medical devices for the minimally invasive diagnosis or treatment of urological disorders primarily urinary stones and other clinical indications. It offers lithotripters, such as Sonolith i-move and Sonolith i-sys for the treatment of urinary tract stones by means of extracorporeal shockwave lithotripsy technology. This division also leases lithotripters; sells disposables and spare parts; and provides maintenance services. The company markets and sells its products through its direct marketing and sales organization, as well as through third-party distributors and agents. Its customers include public and private hospitals, urology clinics, and research institutions. The company was founded in 1979 and is based in Vaulx-en-Velin, France.

About Sunshine Heart

CHF Solutions, Inc., an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. The company was formerly known as Sunshine Heart, Inc. and changed its name to CHF Solutions, Inc. in May 2017. CHF Solutions, Inc. was founded in 1999 and is based in Eden Prairie, Minnesota.

Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply